These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 32117752)

  • 21. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.
    Cambier S; Sylvester RJ; Collette L; Gontero P; Brausi MA; van Andel G; Kirkels WJ; Silva FC; Oosterlinck W; Prescott S; Kirkali Z; Powell PH; de Reijke TM; Turkeri L; Collette S; Oddens J
    Eur Urol; 2016 Jan; 69(1):60-9. PubMed ID: 26210894
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proteome-based classification of Nonmuscle Invasive Bladder Cancer.
    Stroggilos R; Mokou M; Latosinska A; Makridakis M; Lygirou V; Mavrogeorgis E; Drekolias D; Frantzi M; Mullen W; Fragkoulis C; Stasinopoulos K; Papadopoulos G; Stathouros G; Lazaris AC; Makrythanasis P; Ntoumas K; Mischak H; Zoidakis J; Vlahou A
    Int J Cancer; 2020 Jan; 146(1):281-294. PubMed ID: 31286493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations.
    Kassouf W; Traboulsi SL; Schmitz-Dräger B; Palou J; Witjes JA; van Rhijn BW; Grossman HB; Kiemeney LA; Goebell PJ; Kamat AM
    Urol Oncol; 2016 Oct; 34(10):460-8. PubMed ID: 27368880
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
    Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
    Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term follow-up of TaG1 non-muscle-invasive bladder cancer.
    Olivier Bosset P; Neuzillet Y; Paoletti X; Molinie V; Botto H; Lebret T
    Urol Oncol; 2015 Jan; 33(1):20.e1-20.e7. PubMed ID: 25282704
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel nomograms to predict recurrence and progression in primary non-muscle-invasive bladder cancer: validation of predictive efficacy in comparison with European Organization of Research and Treatment of Cancer scoring system.
    Kim HS; Jeong CW; Kwak C; Kim HH; Ku JH
    World J Urol; 2019 Sep; 37(9):1867-1877. PubMed ID: 30535715
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monitoring high-risk bladder cancer.
    Schwentner C; Stenzl A; Gakis G
    Curr Opin Urol; 2012 Sep; 22(5):421-6. PubMed ID: 22814882
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oncological outcome of primary versus secondary muscle-invasive bladder cancer is comparable after radical cystectomy.
    Aziz A; Gierth M; Fritsche HM; May M; Otto W; Denzinger S; Wieland WF; Merseburger A; Riedmiller H; Kocot A; Burger M
    Urol Int; 2013; 91(1):97-102. PubMed ID: 23751372
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interest of next-generation sequencing in BCG-treated high-risk bladder cancer.
    Jungels C; Martinez Chanza N; Albisinni S; Mercier M; d'Haene N; Rorive S; Roumeguère T
    Prog Urol; 2018 May; 28(6):344-350. PubMed ID: 29673906
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recurrence and progression in non-muscle-invasive bladder cancer using EORTC risk tables.
    Altieri VM; Castellucci R; Palumbo P; Verratti V; Sut M; Olivieri R; Manco R; Ricciardulli S; Nicolai M; Criniti P; Tenaglia RL
    Urol Int; 2012; 89(1):61-6. PubMed ID: 22722366
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Calgranulin A (S100A8) Immunostaining: A Future Candidate for Risk Assessment in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC).
    Nicklas AP; Kramer MW; Serth J; Hennenlotter J; Hupe MC; Reimer DU; Stenzl A; Merseburger AS; Kuczyk MA; von Klot CJ
    Adv Ther; 2018 Nov; 35(11):2054-2068. PubMed ID: 30232708
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostaglandin receptors EP1-4 as a potential marker for clinical outcome in urothelial bladder cancer.
    von der Emde L; Goltz D; Latz S; Müller SC; Kristiansen G; Ellinger J; Syring I
    Am J Cancer Res; 2014; 4(6):952-62. PubMed ID: 25520883
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EORTC Risk Model to Predict Progression in Patients With Non-Muscle-Invasive Bladder Cancer: Is It Safe to Use in Clinical Practice?
    Busato Júnior WF; Almeida GL; Ribas CA; Ribas Filho JM; De Cobelli O
    Clin Genitourin Cancer; 2016 Apr; 14(2):176-82. PubMed ID: 26444918
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathology in repeated transurethral resection of a bladder tumor as a risk factor for prognosis of high-risk non-muscle-invasive bladder cancer.
    Tae BS; Jeong CW; Kwak C; Kim HH; Moon KC; Ku JH
    PLoS One; 2017; 12(12):e0189354. PubMed ID: 29244843
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer.
    van Rhijn BW; Liu L; Vis AN; Bostrom PJ; Zuiverloon TC; Fleshner NE; van der Aa MN; Alkhateeb SS; Bangma CH; Jewett MA; Zwarthoff EC; Bapat B; van der Kwast TH; Zlotta AR
    BJU Int; 2012 Oct; 110(8):1169-76. PubMed ID: 22448597
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patient-Derived Non-Muscular Invasive Bladder Cancer Xenografts of Main Molecular Subtypes of the Tumor for Anti-Pd-l1 Treatment Assessment.
    Blinova E; Roshchin D; Kogan E; Samishina E; Demura T; Deryabina O; Suslova I; Blinov D; Zhdanov P; Osmanov U; Nelipa M; Kaprin A
    Cells; 2019 May; 8(6):. PubMed ID: 31159302
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Deregulation of HOX B13 expression in urinary bladder cancer progression.
    Marra L; Cantile M; Scognamiglio G; Perdonà S; La Mantia E; Cerrone M; Gigantino V; Cillo C; Caraglia M; Pignata S; Facchini G; Botti G; Chieffi S; Chieffi P; Franco R
    Curr Med Chem; 2013 Feb; 20(6):833-9. PubMed ID: 23276138
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk-based Management of Non-muscle Invasive Bladder Cancer: Experience from Tribhuvan University Teaching Hospital.
    Luitel BR; Chalise PR; Nathani S; Gupta DK; Subedi P; Chapagain S; Sharma UK; Gyawali PR; Shrestha GK; Joshi BR
    Kathmandu Univ Med J (KUMJ); 2016 Oct.-Dec.; 14(56):352-356. PubMed ID: 29371493
    [TBL] [Abstract][Full Text] [Related]  

  • 39. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.